Pertussis Market to Set Phenomenal Growth From 2025 to 2034

Introduction
Pertussis, commonly known as whooping cough, is a highly contagious respiratory infection caused by Bordetella pertussis. Despite widespread vaccination, pertussis continues to pose a significant public health burden due to waning immunity and outbreaks in both developed and developing countries.
The Pertussis Market is gaining momentum as global health authorities intensify immunization programs, booster schedules, and awareness campaigns. With the advent of combination vaccines and innovations in vaccine delivery, the market is poised for steady growth between 2024 and 2034.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71464

Market Overview
• Market Size 2024: Valued at USD 8.6 billion
• Forecast 2034: Expected to reach USD 14.1 billion
• CAGR (2024-2034): ~5.1%

Key Highlights
• Rising adoption of DTaP and Tdap vaccines across pediatric and adult populations.
• Booster programs expanding in the U.S., Europe, and parts of Asia-Pacific.
• Partnerships between global health agencies (WHO, UNICEF) and vaccine manufacturers improving distribution in low-income countries.
• Strong pipeline for next-generation pertussis vaccines with longer-lasting immunity.

Segmentation Analysis
By Vaccine Type
• Whole-cell Pertussis Vaccines (wP)
• Acellular Pertussis Vaccines (aP)
• Combination Vaccines (DTaP, Tdap, DTP-HepB-Hib, etc.)

By Age Group
• Infants & Children
• Adolescents
• Adults

By Distribution Channel
• Public Health Programs (government & NGO initiatives)
• Private Vaccination Clinics
• Hospital Pharmacies
• Retail & Online Pharmacies

By End User
• Hospitals
• Pediatric Clinics
• Ambulatory Care Centers
• Public Health Agencies

Summary:
Combination vaccines dominate the market, particularly DTaP and Tdap formulations, due to convenience and high compliance rates. While infants remain the largest vaccination group, adolescent and adult booster programs are increasingly critical to reducing transmission.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71464/pertussis-market

Regional Analysis
North America
• Strongest market share in 2024, led by the U.S.
• High coverage of childhood vaccination and mandatory school-entry immunization policies.
• Growth supported by Tdap boosters for adolescents, adults, and pregnant women.
Europe
• Widespread adoption of acellular pertussis vaccines across Western Europe.
• Regular booster schedules for adolescents and adults sustain market growth.
• Focus on catch-up immunization programs in Eastern Europe.
Asia-Pacific
• Fastest-growing region with CAGR ~6.2%.
• Large infant population in China, India, and Southeast Asia driving demand.
• National immunization programs expanding coverage, supported by WHO and UNICEF partnerships.
Latin America
• Brazil and Mexico lead adoption with publicly funded vaccination programs.
• Market growth hindered by vaccine shortages in rural areas.
Middle East & Africa
• Smaller market share but improving access due to global vaccine alliances (e.g., Gavi).
• GCC nations focusing on expanding routine childhood immunization.

Summary:
North America and Europe dominate in terms of booster program penetration, but Asia-Pacific will emerge as the growth engine due to its large pediatric base and expanding government-led vaccination drives.

Market Dynamics
Key Growth Drivers
• Increasing global focus on childhood immunization programs.
• Rising demand for booster vaccines in adolescents and adults.
• Technological advancements in acellular and combination vaccines.
• International collaborations ensuring vaccine access in low-income nations.

Key Challenges
• Waning immunity leading to resurgence of pertussis outbreaks.
• Limited healthcare access and infrastructure in low-income regions.
• Vaccine hesitancy and misinformation in certain geographies.

Latest Trends
• Growth of DTaP-based combination vaccines that reduce the number of injections.
• Research into longer-lasting pertussis vaccines to reduce booster frequency.
• Increasing adoption of maternal immunization programs to protect newborns.
• Expansion of public-private partnerships for affordable vaccine distribution.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71464

Competitor Analysis
Major Players
• Sanofi Pasteur - Daptacel, Adacel
• GlaxoSmithKline plc (GSK) - Infanrix, Boostrix
• Mitsubishi Tanabe Pharma - Pertussis vaccine portfolio in Asia
• Serum Institute of India - DTP and combination vaccines
• Bharat Biotech - Pertussis-containing vaccine formulations
• Biological E Limited - Pentavalent vaccines
• Walvax Biotechnology - Expanding pertussis vaccine capacity in China
• China National Biotec Group (CNBG) - Large-scale pertussis vaccine supply
• PT Bio Farma - Key supplier in Southeast Asia
• Emergent BioSolutions - Partnerships for booster immunization

Competitive Summary:
The market is dominated by Sanofi and GSK, with strong global sales of their DTaP and Tdap products. However, emerging Asian players such as Serum Institute of India, Bharat Biotech, and Walvax Biotechnology are scaling up production, especially for developing regions.

Conclusion
The Pertussis Market is projected to grow from USD 8.6 billion in 2024 to USD 14.1 billion by 2034, at a CAGR of 5.1%. Rising global immunization initiatives, stronger booster programs, and innovations in combination vaccines are the core growth drivers.

While vaccine hesitancy and waning immunity remain challenges, the global push for universal immunization ensures a robust long-term outlook. Emerging markets in Asia-Pacific and Latin America will see the fastest growth, supported by government and NGO-driven programs.
Key Takeaway: Companies investing in affordable, long-lasting combination vaccines and booster programs are best positioned to capture market opportunities over the next decade.

This report is also available in the following languages : Japanese (百日咳市場), Korean (백일해 시장), Chinese (百日咳市场), French (Marché de la coqueluche), German (Keuchhustenmarkt), and Italian (Mercato della pertosse), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71464

Our More Reports:

Inferior Vena Cava Filter Market
https://exactitudeconsultancy.com/reports/71516/inferior-vena-cava-filter-market

Pneumothorax Treatment Device Market
https://exactitudeconsultancy.com/reports/71518/pneumothorax-treatment-device-market

Idiopathic Pulmonary Fibrosis Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71520/idiopathic-pulmonary-fibrosis-patient-pool-analysis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.